Pharmaceutical Companies

Portfolio Pharmaceuticals Botswana has completed a technology transfer from an international manufacturing partner, equipping local specialists with the skills needed to formulate, manufacture, and test medicines while maintaining quality standards.

If completed, the transaction will add Emcitate to ANI’s portfolio, strengthening its position in the rare disease market.

Under the agreement, Boehringer will pay US$358million upfront for access to six biologic programmes, with Sino eligible for up to US$7billion in milestone payments and additional royalties on sales of any commercialised products.

Hinova is also eligible to receive up to approximately US$1.07 billion in additional payments tied to development, regulatory and commercial milestones, as well as tiered royalties on net sales in markets outside Greater China.

The new site will expand AbbVie’s research capabilities and strengthen its presence in one of the UK’s established life sciences clusters.

Lumirix® is the first topical prescription treatment approved in Singapore that directly targets the disease’s pathophysiology, addressing an unmet need among patients with the condition.

Bavarian Nordic originally developed the vaccine in collaboration with the US Government as a smallpox vaccine suitable for a broad population, including people with weakened immune systems who cannot receive traditional replicating smallpox vaccines.

The announcement comes two years after the companies began their collaboration, although neither has explained the delay in publicly disclosing the agreement.

The expanded network will strengthen Lonza’s capacity across bioconjugates, high-potency compounds, viral vectors and lipid-based delivery technologies.

The approval follows a pricing agreement announced in September 2025 involving Unitaid, Wits RHI, the Clinton Health Access Initiative (CHAI) and Dr. Reddy’s.